These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

546 related articles for article (PubMed ID: 18183530)

  • 21. Antipsychotic safety and efficacy concerns.
    Meyer JM
    J Clin Psychiatry; 2007; 68 Suppl 14():20-6. PubMed ID: 18284274
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [New pharmacological approaches to the treatment of schizophrenia].
    Uzbay IT
    Turk Psikiyatri Derg; 2009; 20(2):175-82. PubMed ID: 19504368
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Serotonin and dopamine interactions in rodents and primates: implications for psychosis and antipsychotic drug development.
    Marek GJ
    Int Rev Neurobiol; 2007; 78():165-92. PubMed ID: 17349861
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Schizophrenia: a psychobiological view].
    Rodríguez-Arias M; Aguilar MA; Espert R; Miñarro J
    Rev Neurol; 1996 Oct; 24(134):1210-20. PubMed ID: 8983716
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Schizophrenia treatment. Critical review on the drugs and mechanisms of action of antipsychotics.
    Tajima K; Fernández H; López-Ibor JL; Carrasco JL; Díaz-Marsá M
    Actas Esp Psiquiatr; 2009; 37(6):330-42. PubMed ID: 20066585
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Aripiprazole as "dopamine sensitivity stabilizer"].
    Tadokoro S
    Nihon Rinsho; 2013 Apr; 71(4):684-8. PubMed ID: 23678600
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cognitive function and social abilities in patients with schizophrenia: relationship with atypical antipsychotics.
    Tyson PJ; Laws KR; Flowers KA; Tyson A; Mortimer AM
    Psychiatry Clin Neurosci; 2006 Aug; 60(4):473-9. PubMed ID: 16884450
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pathophysiologic basis for schizophrenia and the efficacy of antipsychotics.
    Ereshefsky L; Tran-Johnson TK; Watanabe MD
    Clin Pharm; 1990 Sep; 9(9):682-707. PubMed ID: 1977544
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neuropharmacology of second-generation antipsychotic drugs: a validity of the serotonin-dopamine hypothesis.
    Kuroki T; Nagao N; Nakahara T
    Prog Brain Res; 2008; 172():199-212. PubMed ID: 18772034
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Advantages and disadvantages of combination treatment with antipsychotics ECNP Consensus Meeting, March 2008, Nice.
    Goodwin G; Fleischhacker W; Arango C; Baumann P; Davidson M; de Hert M; Falkai P; Kapur S; Leucht S; Licht R; Naber D; O'Keane V; Papakostas G; Vieta E; Zohar J
    Eur Neuropsychopharmacol; 2009 Jul; 19(7):520-32. PubMed ID: 19411165
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [The quest for the pharmacological treatment of schizophrenia: from conventional neuroleptics to atypical antipsychotics and beyond].
    Dratcu L
    Vertex; 2010; 21(93):385-93. PubMed ID: 21218203
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Upcoming agents for the treatment of schizophrenia: mechanism of action, efficacy and tolerability.
    Bishara D; Taylor D
    Drugs; 2008; 68(16):2269-92. PubMed ID: 18973393
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [New antipsychotic agents].
    Brochier T
    Rev Prat; 1994 Nov; 44(17):2312-5. PubMed ID: 7984938
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neurotensin-dopamine interactions: relevance to schizophrenia and the action of antipsychotic drugs.
    Stowe ZN; Bissette G; Nemeroff CB
    Yakubutsu Seishin Kodo; 1991 Feb; 11(1):49-59. PubMed ID: 1679273
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents.
    Miyamoto S; Miyake N; Jarskog LF; Fleischhacker WW; Lieberman JA
    Mol Psychiatry; 2012 Dec; 17(12):1206-27. PubMed ID: 22584864
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dopamine and serotonin interactions in the prefrontal cortex: insights on antipsychotic drugs and their mechanism of action.
    Di Pietro NC; Seamans JK
    Pharmacopsychiatry; 2007 Dec; 40 Suppl 1():S27-33. PubMed ID: 18080940
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment of schizophrenia patients: comparing new-generation antipsychotics to each other.
    Fleischhacker WW; Widschwendter CG
    Curr Opin Psychiatry; 2006 Mar; 19(2):128-34. PubMed ID: 16612191
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The complexity of the dopaminergic synapses and their modulation by antipsychotics.
    Leuner K; Müller WE
    Pharmacopsychiatry; 2006 Feb; 39 Suppl 1():S15-20. PubMed ID: 16508891
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Evaluation of antipsychotic and relative drugs using disruption of prepulse inhibition as an animal model for schizophrenia].
    Suemaru K; Kohnomi S; Umeda K; Araki H
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2008 Jun; 28(3):121-6. PubMed ID: 18646597
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Overview of the findings from the European SOHO study.
    Suarez D; Haro JM
    Expert Rev Neurother; 2008 Jun; 8(6):873-80. PubMed ID: 18505352
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.